AMARIN CORP PLC -ADR (AMRN)
US0231112063 - ADR
AMARIN CORP PLC -ADR
NASDAQ:AMRN (11/12/2024, 8:00:00 PM)
After market: 0.54 -0.01 (-2.23%)0.5523
-0.01 (-1.38%)
Company Profile
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Company Info
AMARIN CORP PLC -ADR
First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge
DUBLIN Dublin 2
P: 35316699020
CEO: John F. Thero
Employees: 275
Website: https://amarincorp.com/
AMRN News
2 days ago - Amarin Corporation plcInvestigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual13 days ago - The Motley FoolAmarin Plc (AMRN) Q3 2024 Earnings Call TranscriptAMRN earnings call for the period ending September 30, 2024.
13 days ago - Amarin Corporation plcAmarin Reports Third Quarter 2024 Financial Results and Provides Business Updatea month ago - Amarin Corporation plcAmarin Announces Two Upcoming Investor Eventsa month ago - Amarin Corporation plcAmarin Announces Two Upcoming Investor Events-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November...
2 months ago - Amarin Corporation plcResearch Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th AnnualAMRN Twits
Here you can normally see the latest stock twits on AMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
